BCTX · BriaCell Therapeutics Corp.
$3.64
+0.19 (+5.51%)
At close · Aug 7
Going-concern doubt
— flagged Jun 9, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The uncertainty of the Company’s ability to raise such financial capital casts substantial doubt on the Company’s ability to continue as a going concern.”View the 10-Q filed Jun 9, 2026
Market Cap
$30.01M
Shares
8.70M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.64
Open$3.53
Day$3.46–3.68
52W$2.60–14.68
Avg vol 30d150K
Short int448K · 5.2% float · 1.9d
Short vol55%
Last earningsOct 28, 2022
DataJan 2020–Aug 2026
Filing10-Q · Jun 9
Up next
FQ1-27 quarter ends
~Oct 31, 2026
Est
filed Jun 9, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−35%
below
Price vs 50-day avg
+8%
above
RSI (14)
54
neutral
MACD trend
Negative
52-week position
9%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−8%
trailing
6-month return
−11%
trailing
YTD return
−49%
this year
Relative strength
−24%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
6 of 16 funds reported for Jun 30 · net +54 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.15% of float · ▲ +17.9% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
16 holders — mid 3-yr range
Squeeze score
69
elevated · 0–100
Fundamentals
EPS growth
−42%
Y/Y
Free cash flow
$-28.6M
Valuation
P/E 1.5
in line
Balance sheet
$10.5M
net cash
Quant / Vol
risk profile
Volatility
113%
annualized · 1-yr
Max drawdown
−80%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−35%
Bearish
Price vs 50-day avg
+8%
Bullish
RSI (14)
54
Neutral
MACD trend
Negative
Bearish
52-week position
9%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
6 of 16 funds reported for Jun 30 · net +54 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.15% of float · ▲ +17.9% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
16 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $3
Now $4 · 9%
52-wk high $15
vs 200-day avg -35%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCTX
this stock
BriaCell Therapeutics Corp.
|
$30.01M | -48.8% | — | 1.5 | 5.2% |
|
ONC
BeOne Medicines Ltd.
|
$487.49B | +14.6% | +22179.2% | 749.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.68B | +9.4% | +46.2% | 28.2 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.49B | +1.9% | +20.8% | 19.1 | 3.4% |
|
ARGX
Argenx SE
|
$54.76B | +2.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCTX | +5.8% | -7.6% | -10.6% | +5.8% | -48.8% |
| SPY | +3.5% | +2.4% | +13.4% | +3.5% | +13.4% |
| vs SPY | +2.3% | -10.0% | -24.0% | +2.3% | -62.2% |